Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Daniel Peter Petrylak, Xin Gao, Nicholas J. Vogelzang, Mary Harlow Garfield, Ian Taylor, Marcia Dougan Moore, Ronald Alan Peck, Howard A. Burris | ||||||||||||
Title | First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI). | ||||||||||||
|
|||||||||||||
URL | https://meetinglibrary.asco.org/record/185083/abstract | ||||||||||||
Abstract Text | J Clin Oncol 38: 2020 (suppl; abstr 3500), DOI: 10.1200/JCO.2020.38.15_suppl.3500 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|